USA News Group Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Aug. 12, 2024 /CNW/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns Hopkins Medicine reports that up to 80% of patients are diagnosed at advanced stages, making treatment much more challenging. A recent study in the journal Cell Genomics reveals that key protein biomarkers for early detection have been identified. According to analysts at Research Nester, the pancreatic cancer market is slated to expand by ~18% CAGR between 2024-2035, reaching US$36 billion by 2036. Biotech developers are actively working on innovative treatments to significantly enhance patient health outcomes, with recent developments coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Halozyme Therapeutics, Inc. (NASDAQ: HALO), Candel Therapeutics, Inc. (NASDAQ: CADL), Merus N.V. (NASDAQ: MRUS), and Roche Holding AG (OTCQX: RHHBY).
Read more at newswire.ca